Nanoform Finland Plc and Celanese Corporation provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. Together, the API nanoparticles produced through Nanoform's CESS® technology and the Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nano formed particles also allows smaller implants with sustained release properties to be developed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.942 EUR | -3.38% | -6.18% | +22.52% |
04-11 | Nanoform Finland to Deliver Nanomedicine Technology to Japan | MT |
04-11 | Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
156.7 USD | -2.93% | -0.31% | 17.48B | ||
1.942 EUR | -3.38% | -6.18% | 179M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.52% | 179M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NANOFH Stock
- News Nanoform Finland Oyj
- Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants